REG - Abingdon Health PLC - Notice of Results

Abingdon HealthAnnouncement

17/03/2025 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250317:nRSQ8070Aa&default-theme=true

RNS Number : 8070A  Abingdon Health PLC  17 March 2025

 

Abingdon Health plc

("Abingdon Health" or "the Company")

 

Notice of results

Investor presentation

 

York, U.K. 17 March 2025: Abingdon Health plc (AIM: ABDX), a leading
international developer, manufacturer and distributor of high quality and
effective rapid tests, will announce its unaudited interim results for the six
months ended 31 December 2024 on Monday 24 March 2025.

 

Investor Presentation

The Company will provide a live presentation relating to the preliminary
results via the Investor Meet Company platform on Wednesday 26 March at 11:00
GMT.

 

The presentation is open to all existing and potential shareholders. Questions
can be submitted pre-event via your Investor Meet Company dashboard up until
9am the day before the meeting or at any time during the live presentation.

 

Investors can sign up to Investor Meet Company for free and add to meet
Abingdon Health plc via:

 

https://www.investormeetcompany.com/abingdon-health-plc/register-investor
(https://www.investormeetcompany.com/abingdon-health-plc/register-investor)

 

Investors who already follow Abingdon Health plc on the Investor Meet Company
platform will automatically be invited.

 

Enquiries

 

 Abingdon Health plc                                                             www.abingdonhealth.com/investors/ (http://www.abingdonhealth.com/investors/)
 Chris Yates, Chief Executive Officer                                            Via Walbrook PR
 Chris Hand, Executive Chairman

 Zeus Capital (Sole Broker and Nominated Adviser)                                  Tel: +44 (0) 20 3829 5000
 Antonio Bossi / Alexandra Campbell-Harris (Corporate Finance)
 Fraser Marshall (Corporate Broking)

 Walbrook PR (Media & Investor Relations)      Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
                                               (mailto:abingdon@walbrookpr.com)
 Paul McManus / Alice Woodings                 Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654
 Phillip Marriage                              +44 (0)7867 984 082

 

 

About Abingdon Health plc

Abingdon Health is a leading med-tech contract service provider offering its
services to an international customer base.

 

The Group's CDMO division (https://www.abingdonhealth.com/services/) offers
lateral flow product development, regulatory support, technology transfer and
manufacturing services for customers looking to develop new assays or transfer
existing laboratory-based assays to a lateral flow format. Abingdon Health's
CDMO division has the internal capabilities to take lateral flow projects, in
areas such as infectious disease and clinical testing, including companion
diagnostics, animal health and environmental testing, from initial concept
through to routine and large-scale manufacturing; from "idea to commercial
success".

 

Abingdon's regulatory services companies, Compliance Solutions (Life Sciences)
(https://cslifesciences.com) and IVDeology (https://www.ivdeology.co.uk) ,
provide a broad range of regulatory services to the in vitro diagnostic and
wider medical device industry, to support customers in bringing products to
market across a range of territories including the USA, EU and the UK. Our
consultancy services range from design, implementation and maintenance of
quality management systems, preparation of technical files for regulatory
approvals, part-time and interim management support, auditing both internally
(e.g. Quality Management Systems) and externally (e.g. critical suppliers),
management reviews and presentations, training and mentoring.

 

Abingdon Health's Abingdon Simply Test range of self-tests is an e-commerce
platform that offers a range of self-tests to empowers consumers to manage
their own health and wellbeing. The Abingdon Simply Test
(http://www.abingdonsimplytest.com) e-commerce site offers consumers a range
of information to support them in making informed decisions on the tests
available. In addition, the site provides Abingdon's contract services
customers with a potential route to market for self-tests. The Abingdon Simply
Test range and other selected self-test products, such as the saliva pregnancy
test, Salistick (https://www.salignostics.com/salistick/) (TM
(https://www.salignostics.com/salistick/) ), is also sold through
international distributors and through other channels in the UK and Ireland,
such as pharmacy chains.

 

Founded in 2008, Abingdon Health is headquartered in York, England with
CDMO facilities in both York, UK and Madison, Wisconsin, USA. For more
information visit: www.abingdonhealth.com (http://www.abingdonhealth.com/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORBLGDXBUBDGUS